NEW YORK, Aug. 12, 2009 (GLOBE NEWSWIRE) -- Prana Biotechnology (ASX:PBT) (Nasdaq:PRAN) today announced that it has received a Notice of Allowance from the United States Patent and Trade Mark Office (USPTO), protecting its clinical asset, PBT2, in the USA. The patent entitled, ‘8-Hydroxyquinoline derivatives’ covers the composition of matter of selected families of 8-Hydroxyquinoline compounds, including PBT2 and pharmaceutical compositions containing these compounds.
